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Abstract: 
 
The preparation and biological activity of various structural analogs of the malbrancheamides are 
disclosed. The impact of indole chlorination, C-12a relative stereochemistry, and 
bicyclo[2.2.2]diazaoctane core oxidation state on the ability of these analogs to inhibit 
calmodulin dependent phosphodiesterase (PDE1) was studied, and a number of potent 
compounds were identified. 
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Article: 
 
The synthesis, biosynthetic investigations, and biological activities of a number of unique 
prenylated indole alkaloids containing a characteristic bicyclo[2.2.2]diazaoctane core has been 
the focus of vigorous research in our laboratory1 and that of other research groups2 for a number 
of years. This class of highly biologically active fungal metabolites includes the 
paraherquamides,3 brevianamides,4 notamides,5 stephacidins,6 and malbrancheamides7 (Fig. 1) 
among others, and the range of biological activities exhibited by a number of representative 
members of this class is quite striking. We have previously disclosed that malbrancheamide is a 
calmodulin (CaM) antagonist that inhibits the activity of CaM-dependent phosphodiesterase 
(PDE1) in a concentration-dependent manner.7 
 
 
Figure 1. Structures of malbrancheamide and malbrancheamide B. 
 
Calmodulin is an important drug target for the development of naturally and synthetic 
therapeutically useful agents due to its involvement in a variety of cell functions throughout the 
regulation of more than 50 enzymes and ion channels. Such proteins include several kinases, 
PDE1, calcineurin, the nitric oxide synthases, adenylate cyclases 1 and 8, several ion channels, 
caldesmon, spectrin, and adducin, among others. Indeed, certain anti-psychotic, anti-tumoral, 
smooth muscle relaxants, α-adrenergic blocking, immunostimulant and cytoprotective drugs 
exert their therapeutic action by inhibiting CaM.8 
 
The bicyclo[2.2.2]diazaoctane core common to these natural products is proposed to arise 
biosynthetically by an intramolecular hetero-Diels-Alder reaction of a 5-hydroxypyrazin-2(1H)-
one,2 and work from this laboratory has provided a provocative body of experimental evidence to 
support such a hypothesis.1 Indeed, we have applied biomimetic hetero-Diels-Alder 
cycloaddition strategies to prepare several prenylated indole alkaloids, including stephacidin 
A,9 brevianamide B,10 marcfortine C,11 notoamide B,9b VM55599,12 and most recently, 
malbrancheamide and malbrancheamide B.13 Due to the significant biological activity of both 
malbrancheamide and malbrancheamide B, a program aimed at determining the effect of various 
structural features of the malbrancheamides on their biological activities was initiated. 
Specifically, we endeavored to explore how indole chlorination, relative stereochemistry, and 
bicyclo[2.2.2]diazaoctane core oxidation state altered the ability of these analogs to inhibit CaM 
throughout the analysis of their effect on PDE1 activity. We chose these structural parameters 
since the malbrancheamides were the first members of this family of alkaloids to be identified 
with a halogenated indole ring. The brevity and high overall yield of our synthetic approach to 
these substances has allowed us to readily access a number of malbrancheamide analogs with the 
desired structural and stereochemical variability. 
 
A Fischer indole strategy was first devised to prepare a number of malbrancheamide analogs 
containing the unnatural relative stereochemistry at C-12a.14 Ketone 1 was condensed with 3,4-
dichlorophenylhydrazine followed by Fischer indole synthesis to give a mixture of regioisomers 
2 and 3 in modest yield (Scheme 1). Treatment of 2 or 3 with DIBAL-H led to a 1:1 mixture of 
the reduced tertiary lactam, 4 or 5, respectively, and the reduced secondary lactam, 6 or 7, 
respectively, in good yield. While this route proved useful in generating an array of structural 
diversity, the low yield of the Fischer indole sequence prompted investigation of other synthetic 
strategies. 
 
 
Scheme 1. Fischer indole synthesis. 
 
A more efficient synthetic strategy involved a biomimetic hetero-Diels-Alder reaction as the key 
step (Scheme 2).13 Enamides 8a–8d could be easily prepared,13 and treatment with basic 
methanol resulted in tautomerization followed by cycloaddition to give a mixture of 
diastereomeric cycloadducts 10a–d as well as 2 and 11a–c with the syn-products 10a–
d predominating. The ready availability of the Diels-Alder precursors 8a–d allowed the 
preparation of analogs 10a–c, 2, and 11a–d with a variety of chlorination substitution patterns. 
 
 
Scheme 2. Hetero-IMDA reactions. 
 
Next, the effect of the bicyclo[2.2.2]diazaoctane core oxidation state was interrogated. Thus, 
treatment of and 10a–d with DIBAL-H led to selective reduction of the tertiary amide 
functionality to provide the tertiary amines 12–15 in good yields (Scheme 3). 
 
 
Scheme 3. Amide reductions. 
 
Table 1. Inhibition of CaM–PDE1 by compounds 2–7 and 10–15. 
Compound IC50 (μM) Chlorpromazine Potency 
2 33.92 ± 4.64 16.78 ± 3.99 0.5 
3 45.41 ± 2.39 10.76 ± 0.41 0.2 
4 134.47 ± 12.63 10.76 ± 0.41 0.1 
5 11.95 ± 1.05 10.76 ± 0.41 0.9 
6 81.24 ± 4.46 10.76 ± 0.41 0.1 
7 27.51 ± 3.13 10.76 ± 0.41 0.4 
10a 18.57 ± 2.87 16.78 ± 3.99 0.9 
10b 31.49 ± 2.52 14.11 ± 1.75 0.4 
10c 61.79 ± 5.48 14.11 ± 1.75 0.2 
10d 150.66 ± 26.79 16.78 ± 3.99 0.1 
11a 62.34 ± 4.58 14.11 ± 1.75 0.2 
11b 42.77 ± 1.66 14.11 ± 1.75 0.3 
11c 23.61 ± 4.21 16.78 ± 3.99 0.7 
12 15.99 ± 0.87 16.78 ± 3.99 1.1 
nat. 12 19.33 ± 1.40 16.78 ± 3.99 0.9 
13 60.33 ± 6.84 14.11 ± 1.75 0.2 
14 42.85 ± 4.22 14.11 ± 1.75 0.3 
nat. 14 183.28 ± 37.58 14.11 ± 1.75 0.1 
15 35.73 ± 3.01 16.78 ± 3.99 0.5 
Potency was obtained by the formula: IC50 (chlorpromazine)/IC50 (compound), assuming a value 
of 1.00 for chlorpromazine. 
 
Anti-CaM activity was measured as previously described by an enzymatic functional assay using 
PDE1 as monitoring enzyme,15 and the data are summarized in Table 1. Upon examination, some 
surprising results are apparent. Indole chlorine substitution does have a distinct effect on PDE1 
activity, however an overall structure–activity relationship with regard to chlorine substitution is 
mostly absent. For example, the syn-dioxopiperazines 10a–d exhibit potencies from 0.9 to 0.1, 
with the dichloro substituted species 10a displaying the highest potency (0.9) and the 
monochloro substituted analogs 10b and 10c displaying roughly equivalent potencies (0.4 and 
0.2, respectively). Compound 10d, which lacks chlorine substitution, was virtually inactive. 
Comparison of these results with the potencies of the anti-dioxopiperazines 2, 3, and 11a–
c revealed that compound 11c, which completely lacks chlorine substitution, was the most active 
substance of this group studied, with a potency 0.7 times that of the positive control. The 
analogs 11a, 11b, 2, and 3 exhibited moderate potencies. Among the monooxopiperazines 4–
7 and 12–15, synthetic d,l-malbrancheamide (12) and 5 were the most potent whereas C-12a-epi-
malbrancheamides (4 and 6) were the least potent. It is particularly striking that the 
monooxopiperazine compound 4 (C12a-epi-malbrancheamide) was essentially inactive (potency 
of 0.1) whereas the corresponding C5-oxo-isomer 5 was very potent (0.9). The relative lack of 
activity of compounds 4 and 6 reveals that the relative stereochemistry at C-12a is quite 
important and also reveals the significance of the C5 and C14 amide carbonyl residues. Varying 
indole chlorine substitution on the 7-, 8-, and 9-positions led to potencies ranging from 0.1 to 
0.9. The relative potencies of synthetic, racemic malbrancheamide (12) and malbrancheamide B 
(14) are particularly notable, as it appears to be slightly more active than naturals, optically pure 
(+)-malbrancheamide and malbrancheamide B relative to chlorpromazine, the control inhibitor. 
 
In conclusion, a number of malbrancheamide analogs have been prepared with differing indole 
chlorine substitution, C-12a relative stereochemistry, and bicyclo[2.2.2]diazaoctane core 
oxidation level. Phosphodiesterase activity for each analog was measured alongside 
chlorpromazine, and a number of active compounds were identified (5, 10a, 11c, and 12). The 
overall results revealed that natural malbrancheamide, either the natural (+)-enantiomer or as a 
racemate, are the most active CaM–PDE1 complex inhibitors. The unnatural enantiomers of 
malbrancheamide (12) and malbrancheamide B (14) must be more active than the naturally 
occurring enantiomers. Considering the increased relative potency of racemic malbrancheamides 
compared to that of the natural enantiomerically pure substances, efforts are underway to prepare 
their enantiomerically pure versions to interrogate the absolute stereochemical issue in more 
detail. The broad synthetic technology platform our laboratory has developed to synthesize both 
racemic as well as optically pure versions of this family of prenylated indole alkaloids is being 
exploited to prepare a number of additional analogs of the malbrancheamides for biological 
evaluation. 
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